ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with resid...
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant therapy and inform future adjuvant therapy trials. We aim to investigate the impact of circulating tumor DNA (ctDNA) status...
Alternative Titles
Full title
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_00318f24d99f4b07bfee5dde9a0b9a2e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_00318f24d99f4b07bfee5dde9a0b9a2e
Other Identifiers
ISSN
2374-4677
E-ISSN
2374-4677
DOI
10.1038/s41523-023-00512-7
